Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
3/30/26 Ferrer Tyvaso for Pulmonary Fibrosis Subscribers Only Subscribers Only Subscribers Only
3/30/26 Ferrer Tyvaso for Idiopathic Pulmonary Fibrosis (IPF) Subscribers Only Subscribers Only Subscribers Only
3/30/26 Merck & Co. (MRK) enlicitide decanoate for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
3/30/26 Ionis Pharmaceuticals (IONS) ION904 for Hypertension (Systemic) Subscribers Only Subscribers Only Subscribers Only
3/30/26 Gan & Lee Pharmaceuticals GZR-4 for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results